Medicines and Healthcare Products Regulatory Agency promises research overhaul with “innovative and pragmatic approach”
The UK’s medicines regulator has promised to overhaul the country’s clinical trials system over the next two years, making it more easy for researchers to run cutting-edge studies and building on lessons learned during the pandemic.
In its 2021-23 delivery plan, published on 4 July, the Medicines and Healthcare Products Regulatory Agency promises a “new era in enabling regulation, regulatory science and best evidence”.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.